NovoMix 30
Phase 3Small molecule
NovoMix 30 is one of 41 small molecule programs targeting Type 2 Diabetes Mellitus. It is currently in Phase 3.
2
Indications
4
Total Trials
0
Active Trials
40
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
676 competitors in Type 2 Diabetes Mellitus
#DrugCompanyPhaseTrials
1NovoMix 30
GGeropharm
Phase 3
Tanzeum
GSKPreclinical
Adenocard
AstellasPreclinical
NOVOLIN R
Novo NordiskPreclinical
Cipro
BayerPreclinical
Myrbetriq
AstellasPreclinical
Dostinex
PfizerPreclinical
Golytely
BayerPreclinical
Lantus
SanofiPreclinical
Lixisenatide
SanofiPreclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Type 2 Diabetes Mellitus1 trial
Latent Autoimmune Diabetes in Adults1 trial
Randomized Controlled Trial of Insulin Versus Tablets for Latent Autoimmune Diabetes in Adults (LADA)
Unknown status·—·N/A·NCT00776607·200 enrolled
Tics1 trial
Unspecified1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for NovoMix 30. EMBL-EBI & Wellcome Sanger Institute.
- [4]